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Protocol
AbstrACt
Introduction The symptoms of cow’s milk protein allergy 
(CMPA) in infancy can be non-specific which may delay 
a correct diagnosis and cause adverse clinical outcomes. 
The diagnosis of non-IgE-mediated CMPA is particularly 
complex as it involves a 2 to 4 week elimination diet 
followed by oral food challenge (OFC). The Cow’s Milk-
related Symptom Score (CoMiSS) is a clinical resource 
for primary healthcare providers which aims to increase 
awareness of CMPA symptoms to facilitate an earlier 
diagnosis. The aim of the present study is to assess if 
the CoMiSS can be used as a potential diagnostic tool in 
infants with suspected CMPA.
Methods and analysis Exclusively formula-fed infants 
aged 0–6 months presenting with symptoms suggestive 
of CMPA will be included in this prospective, multicentre 
trial which will be conducted in 10 centres in China. All 
infants will commence a 2-week trial of an amino acid-
based formula (AAF) while eliminating all cow milk protein 
from their diets. After the AAF treatment period, infants 
will undergo an open OFC in hospital with standard cow’s 
milk formula, followed by an open home challenge for 
another 2 weeks. Clinical symptoms will be documented 
on standardised symptom scorecards. The CoMiSS will 
be determined at study entry (CoMiSS 1, before the start 
of the AAF), after 2 weeks (CoMiSS 2, before the OFC) 
and after a further period of 2 weeks or when symptoms 
suggestive of CMPA reappear (CoMiSS 3). Weight and 
length will be measured at each visit. The difference 
between CoMiSS 1 and 2 as a predictor of the OFC 
outcome will also be assessed. The diagnostic accuracy of 
the baseline CoMiSS will be calculated. 
Ethics and dissemination The study was approved by 
the Hunan Children's Hospital Medical Ethics Committee, 
Hunan, China. The findings of this trial will be submitted 
for publication in a peer-reviewed journal in paediatric 
nutrition or gastroenterology. Abstracts will be submitted to 
the relevant national and international conferences.
trial registration number NCT03004729; Pre-results.
IntroduCtIon  
Cow’s milk protein allergy (CMPA) is one of 
the major food allergies in infants with an 
estimated prevalence of 2%–5%.1 The diag-
nosis of CMPA remains a clinical challenge as 
many symptoms are non-specific.1 2 Non-IgE 
mediated CMPA is particularly difficult to 
diagnose as the time between contact with the 
offending protein and onset of allergic symp-
toms is delayed, while IgE-based testing with 
cow’s milk-specific IgE or skin prick testing is 
usually negative.3 This often leads to misdiag-
nosis or a delay in obtaining the correct diag-
nosis and appropriate management.4 
The Cow’s Milk-related Symptom Score 
(CoMiSS; figure 1) was developed to increase 
awareness of mainly non-IgE mediated 
strengths and limitations of this study
 ► The CoMiSS was developed by an expert panel as an 
awareness tool for cow’s milk protein allergy (CMPA) 
in infants and is based on a panel of common aller-
gic symptoms.
 ► The findings of this trial are likely to increase the 
awareness for cow’s milk-related symptoms and 
may facilitate an earlier diagnosis of CMPA in infants 
in the primary care setting.
 ► A limitation of the study is that the CoMiSS will 
be validated against open oral food challenges 
rather than double-blind, placebo-controlled food 
challenges.
 ► In addition, the study design may not allow to re-
liably distinguish between IgE-mediated CMPA, 
non-IgE-mediated CMPA and non-allergic cow’s 
milk-related symptoms.
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CMPA.5 Expert clinicians experienced in managing chil-
dren with gastrointestinal (GI) problems and/or atopic 
diseases reviewed the literature to determine whether a 
clinical score derived from symptoms associated with the 
ingestion of cow’s milk protein (CMP) could increase 
the awareness of primary healthcare providers for cow’s 
milk-related symptoms. The CoMiSS tool provides a 
score that considers general allergic manifestations, as 
well as dermatological, GI and respiratory symptoms 
(total score range 0–33). Some allergic symptoms, such 
as vomiting, rectal bleeding or failure to thrive, are not 
included in the score. The score was conceived as an 
awareness tool for cow milk allergy (CMA). The CoMiSS 
may also be used to monitor the evolution of symptoms 
in response to a therapeutic intervention.5 At present, 
the recommended diagnostic approach for CMPA 
relies on a 2 to 4 week elimination diet followed by an 
oral food challenge (OFC).3 While the double-blind, 
placebo-controlled food challenge (DBPCFC) is the 
gold standard for the diagnosis of food allergy, in clin-
ical practice open challenges are generally considered 
sufficient, particularly in infants and young children.3 6 
Parents are often reluctant to proceed with a food chal-
lenge as CMPA symptoms may recur during a positive 
OFC.7 A validated score which could replace or reduce 
the need for food challenges would therefore be of great 
clinical value.
MEthods And AnAlysIs
This single-blinded, prospective, multicentre study will be 
conducted in formula-fed infants with symptoms suggestive 
of CMPA. The trial design is based on current best clinical 
practice, that is, a cow’s milk protein-free elimination diet 
followed by OFC.3 All dietary interventions of the study are 
open label, while investigators involved in the OFC will be 
blinded to the response to amino acid-based formula and 
CoMiSS results. Thus, the study remains single-blinded 
for the comparison of the OFC and CoMiSS results. The 
CoMiSS will be determined by an investigator (not involved 
with the OFC) at study entry, after 2 weeks of an elimination 
diet (before the OFC) and 2 weeks after the reintroduction 
of cow’s milk or whenever symptoms reoccur during the 
open-home challenge.
study objectives
The primary objective of this trial is to validate the change 
in CoMiSS from baseline to week 2 (Δ=CoMiSS 1–CoMiSS 
2) against the reference standard, the OFC to cow’s milk 
formula as a predictor of CMPA.
Secondary objectives are:
1. To determine the sensitivity and specificity of the 
change in CoMiSS from baseline to week 2, based on 
the optimal cut-off on the receiver operating charac-
teristic (ROC) curve.
2. To determine if the CoMiSS 1 (baseline) is predictive 
of OFC outcome.
3. To compare the visit 2 CoMiSS following exclusive 
treatment with amino acid formula (AAF) with his-
torical CoMiSS data sets of healthy infants.
4. To determine if CoMiSS decreases over time in sub-
jects on an AAF diet.
5. To determine if a high CoMiSS at baseline predicts 
a greater absolute decrease in CoMiSS following an 
AAF diet (change from baseline to visit 2)
6. To analyse the symptom components of CoMiSS (cry-
ing, regurgitation, stool consistency, eczema, urticar-
ia and respiratory symptoms).
7. To assess the impact of a family history of atopy on 
baseline CoMiSS and the percentage of subjects with 
confirmed CMPA.
8. To assess the impact of delivery mode (vaginal vs 
Caesarean section) on baseline CoMiSS and the per-
centage of subjects with confirmed CMPA.
9. To monitor the subjects’ growth.
10. To evaluate the therapeutic effect of an elimination 
diet.
11. To measure compliance with an elimination diet.
Clinical setting and study population
The recruitment of the study subjects will take place in 
10 paediatric departments throughout China (for list of 
clinical sites please refer to Acknowledgements section). 
Exclusively formula-fed infants under 6 months of age 
with symptoms suggestive of CMPA are eligible for inclu-
sion in the study. Patients will be consecutively enrolled 
according to the inclusion and exclusion criteria, without 
regard to the severity of symptoms (table 1; figure 2). 
Symptoms need to have been present for at least 
1 week and have developed within the first 2 months of 
commencing an infant formula containing intact CMP. 
Infants considered for inclusion should, in the opinion 
of the investigator, benefit from a 2-week elimination diet 
with an AAF, followed by an OFC.
Inclusion criteria for participation in the study defined
1. Male or female infants aged up to 6 months.
2. Infant exclusively fed with cow’s milk-based formula 
for at least 1 week.
3. Symptoms suggestive of CMPA have been present for 
at least 1 week and have developed within the first 
2 months of starting cow’s milk-based formula.
4. Infant likely to benefit from a 2-week trial of AAF (as 
per investigator’s assessment).
5. Gestational age >37 to<42 weeks.
6. Birth weight between 2500 g and 4500 g.
7. Informed consent signed by either the parent or 
the legal guardian.
Exclusion criteria defined
1. Subject has received extensively hydrolysed or amino 
acid-based formula prior to enrolment.
2. Fever>38.5°C at time of enrolment.
3. History of serious allergic reaction, suggestive of ana-
phylaxis (medically diagnosed).
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Figure 1 CoMiSS.All parameters included in the CoMiSS (evaluation of regurgitation: see ref 11; evaluation of stool 
composition: see ref 12). CoMISS, Cow's Milk-related Symptom Score.
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Table 1 Schedule of events
Assessments and visits
Screening 
visit
Visit 1
baseline
Elimination 
diet with
AAF Visit 2
Home OFC (subjects 
with no reaction to 
CMP at visit 2)
Visit 3 
completion
Early 
withdrawal 
visit
Day 0
(or 
maximum 
2 days 
before day 
0)
Day 0 Day 1 to 
day 14
Day 15
±4 days
Day 15 until reaction; 
or day 15 to day 28 if 
no reaction
Day 29±4 days
(or within 
4 days 
following 
reaction)
0 to 4 days 
after stopping 
study 
procedures
Eligibility/Informed 
Consent
X
Medical history, including 
subject’s results for 
allergen-specific IgE and 
skin prick test (if available)
X
Document delivery mode X
Document demographic 
data
X
Infant length and head 
circumference
X
Infant weight X X X X
Investigator VAS score X X
CoMiSS (including physical 
examination; performed 
by designated site staff 
member)
X X X X
Two-week elimination diet 
with Alfamino formula
X
Provide daily subject intake 
record
X X*
In-hospital open OFC 
(including physical 
examination)
X
Two-week home OFC with 
NAN formula
X*
Prescribe and dispense 
Alfamino formula
X† X‡
Prescribe and dispense 
cow’s milk formula
X§
Concomitant medications X X X X X
Adverse events (including 
SAEs)
X X X X
Collect subject intake 
record
X X X
Record allergy status 
(physical examination)
X
*For subjects with no immediate reaction to cow’s milk formula at visit 2. 
†For subjects with reaction to cow’s milk at visit 2. These subjects should be commenced on Alfamino formula (with follow-up by treating 
medical team). 
‡For subjects with reaction to cow’s milk at visit 3. These subjects should be commenced on Alfamino formula (with follow-up by treating 
medical team).
§For subjects with no reaction to cow’s milk formula at visit 3.
AAF, amino acid-based formula; CMP, cow's milk protein; CoMISS, CoMISS, Cow's Milk-related Symptom Score; OFC, oral food challenge; 
SAEs, serious adverse events; VAS, Visual Analogue Scale. 
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4. Use of antibiotics at enrolment (may participate if an-
tibiotics discontinued for at least 7 days prior to en-
rolment).
5. Infant with medical condition or family situation 
which would preclude participation in the study (ac-
cording to assessment of the investigator).
6. Infant or infant’s parent unable to comply with trial 
procedures.
7. Participation in another clinical trial within 4 weeks 
prior to enrolment.
8. Inability to obtain informed written consent from par-
ent or legal guardian.
Interventions
All study materials, including the CoMiSS tool were 
translated into Chinese language and approved by the 
local investigator team. At study entry, the investigator 
will determine the baseline CoMiSS (CoMiSS 1). Allergy 
testing (total IgE, milk-specific IgE and skin prick testing) 
may be performed, as clinically indicated, but is not a 
protocol requirement. The study consists of the following 
phases: a screening visit (visit 0), a baseline visit (visit 
1) and a 2-week elimination diet during which patients 
exclusively receive AAF. A study visit (visit 2) will take 
place at the end of these 2 weeks. At visit 2, the inves-
tigator will assess if the elimination diet was clinically 
effective, or not, and CoMiSS 2 will be determined. This 
will be followed by a hospital-based, open OFC using a 
cow’s milk-based infant formula with intact CMP. Subjects 
who do not react during the hospital-based challenge 
will continue the OFC at home for up to 2 weeks (visit 
3). Subjects who react to CMP during the home-based 
OFC will stop the OFC before 2 weeks and will return to 
the study centre for visit 3. Infants reacting during the 
OFC will be examined by the investigator, either when 
the parents make contact or, at the latest, after 2 weeks. 
The investigator will determine the CoMiSS (CoMiSS 3) 
at visit 3. Subjects with a positive OFC during the hospi-
tal-based challenge will complete visit 3 assessments on 
the same day as visit 2.
Elimination diet trial with AAF
The 2-week elimination diet will be performed using an 
AAF (Alfamino, Nestlé SA, Vevey, Switzerland). Alfamino 
Figure 2 Study design. CMPA, cow’s milk protein allergy; CoMISS, Cow's Milk-related Symptom Score. 
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is a hypoallergenic, amino-acid based, nutritionally 
complete powdered specialty infant formula containing 
amino acids, carbohydrates, fats, vitamins, minerals, 
trace elements and the long-chain polyunsaturated fatty 
acids, arachidonic acid and docosahexaenoic acid. The 
planned duration of the elimination diet is based on 
published guidelines on the diagnosis and treatment of 
CMPA.3 8 Formula will be prepared by the infant’s care-
giver according to the standard instructions provided on 
the tin.
oFC
The open OFC will be conducted in hospital by a 
medically qualified study investigator. All investiga-
tors will be trained in the food challenge procedure, 
including watching a standardised training video in 
Chinese language. The doctor supervising the OFC is 
blinded to the CoMiSS scores. The cow’s milk-based 
infant formula NAN1 (Nestlé SA, Vevey, Switzerland) 
will be administered during the OFC. The OFC involves 
a typical dose escalation while observing for clinical 
symptoms. The OFC will be performed in hospital on 
day 1 and continued at home for a full week, as toler-
ated. The following doses will be administered during 
of the OFC: initial test dose of one drop on the lip of 
the infant; if no reaction is observed after 15 min, 0.5 mL 
are given orally. If no reaction is observed after 30 min, 
the following oral doses are administered at 30 min 
intervals, as tolerated: 1 mL, 3 mL, 10 mL, 30 mL, 50 mL 
and 100 mL (maximum cumulative dose 194.5 mL). 
Symptoms during OFC will be carefully documented. 
The OFC will be categorised as ‘positive’ or ‘negative’ 
according to symptoms and the assessment by the inves-
tigator. The OFC is considered positive in the pres-
ence of immediate symptoms (vomiting, hives, facial 
angioedema, wheeze, stridor) during day 1 in hospital 
or delayed-onset symptoms (vomiting, increased 
regurgitation, persistent diarrhoea, increased eczema, 
irritability/persistent crying) during the remaining 
week. In case of a positive OFC, infants will remain on 
AAF and will be followed up by their treating clinician.
discontinuing study interventions and patient withdrawal
Subjects may discontinue the study intervention prema-
turely for the following reasons: (1) the subject’s 
parents or legal guardian request to leave the trial; (2) 
the subject is lost to follow-up; (3) in the investigator’s 
opinion, continuation in the trial would be detrimental 
to the subject’s well-being; (4) a major protocol violation 
occurred (in case of a minor protocol violation, the spon-
sor’s clinical project manager will evaluate with the investi-
gator, if the subject has to be withdrawn); (5) a prohibited 
diet/treatment/medication defined in the protocol is 
used during the study (in the event a subject is found 
to be taking such a diet/treatment/medication during 
the trial, the site should immediately contact the clinical 
project manager; the decision to withdraw the subject 
will be made in conjunction with the investigator); (6) 
the sponsor or Independent Ethics Committee decides to 
terminate trial.
If a subject discontinues the intervention or chooses 
to discontinue the intervention prematurely, an early 
withdrawal visit will be completed without delay but no 
later than 4 days after discontinuation. The reason(s) for 
premature discontinuation will be documented accord-
ingly. Every effort will be made to follow-up subjects who 
terminate prematurely to determine the final clinical 
outcome. 
Patient and public involvement statement
No parents or patient advocate groups were involved in 
the planning of this study. Patients were recruited via the 
investigators at medical clinics in China. Once the study 
results have been published in a peer-reviewed journal, a 
summary of the main study findings will be distributed in 
Chinese language via the local investigator teams to the 
participating families.
stAtIstICAl AnAlysIs
The main objective of the trial is to validate the CoMiSS 
(index test) as a predictor of CMPA, as confirmed by a 
positive OFC (reference test). The ROC curve for the 
CoMiSS will be evaluated based on this prediction and 
the area under the curve (AUC) of the ROC curve be 
calculated. The ROC curve is the curve of true positive 
rate (sensitivity) versus false positive rate (1-specificity) 
for different thresholds of the CoMiSS (change from 
baseline). The hypothesis to be tested is:
  H0 : AUC = 0.75 vs. H1 : AUC > 0.75  
The CoMiSS instrument scores range from 0 to 33. An 
AUC >0.75 corresponds to a 1-point ROC curve with 90% 
sensitivity and 60% specificity. Based on this threshold, we 
aim to identify a meaningful CoMiSS cut-off that would 
provide a high sensitivity (around 80%–90%) to pick-up 
all infants suspected of CMPA and minimise the number 
of infants that have a CoMiSS below the proposed 
threshold and would have a positive OFC and moderate 
specificity in the range of 60%–70% for predicting a posi-
tive OFC (ie, diagnosis of CMPA).
All statistical analysis will be performed using the statis-
tical software package R V.3.2.2. Statistical significance 
will be tested at the two-sided 5% level, unless otherwise 
specified. Continuous safety and effectiveness parameters 
will be summarised by presenting the number of patients, 
mean, SD, median, minimum, maximum by formula 
group (test or control). Tabulation of categorical param-
eters by formula group will include counts and percent-
ages;95% CIs will be provided, as appropriate.
randomised analysis plan
For the validation process, the study subjects will be 
randomised 1:1 into a training set and a holdout set. A 
logistic regression model will be fitted to the training set 
(50% of the overall sample), regressing the odds of having 
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a positive OFC on the change in CoMiSS from baseline to 
week 2. This model will then be used to predict the CMPA 
status (positive or negative challenge test) of the subjects 
in the holdout set based on their change in CoMiSS and 
a ROC curve will be derived based on these predictions.
The following effects will be estimated:
 ► AUC of the ROC with 95% CI.
 ► Sensitivity, specificity, negative and positive predic-
tive values, as well as negative and positive likelihood 
ratios with 95% CIs for the optimal threshold of the 
change in CoMiSS.
Different logistic regression models based on using 
different CoMiSS change cut-offs will be tested within 
the training set using cross-validation methods, adjusting 
covariates to choose a model with the highest predictive 
accuracy (using cross-validation) and with the best good-
ness of fit. The selection of the best predictive model 
based on the cross-validation will provide the basis for 
predicting the OFC outcomes in the test infants. The 
prediction will be obtained as the probability (between 
0 and 1) of a positive OFC after 2 weeks. Using different 
thresholds on this probability, several 2×2 contingency 
tables will be obtained. For each 2×2 table, the sensitivity 
(true positive) is defined as the proportion of infants 
positive on the OFC who were also predicted as positive 
using the particular cut-off on the predicted probabilities. 
Specificity (true negative) is defined as the proportion of 
infants negative on the OFC who were also predicted as 
negative using the particular probability cut-off. In addi-
tion to specificity and sensitivity, positive and negative 
predictive values, as well as positive and negative likeli-
hood ratios will be calculated. The AUC of each ROC will 
be used to determine the overall accuracy of the predic-
tion and to choose an optimal probability threshold for 
the use of CoMiSS in clinical practice.
sample size calculation
The hypothesis of interest is that the AUC >  A0  (=0.75) 
and is tested using the test-statistic
  
Z= Â−A0√
Var 0(AUC)  
where Â is the estimated AUC on the holdout set, 
 A0 = 0.75  is the benchmark or minimum clinically rele-
vant AUC of the ROC curve and  Var0(A)  is the variance 
of the AUC under the null hypothesis  H0 . The variance of 
the AUC at a given value A is given by Hajian-Tilaki9
  
VarA(AUC) = 0.0099 e
− a22
(
5a2+8
nd
+ a
2+8
nh
)
,
  
where  a=
√
(2)Φ−1(A)  Φ is the cumulative distribution 
function of the standard normal distribution  n−  and 
 n+  and are the number of subjects in the holdout set who 
test negative and positive in the OFC, respectively.
The corresponding sample size for the required 
number of subjects who would test positive on the OFC 
test when the assumed AUC is A is given by:
 
 
n+ =
[
zα/2
√
V0(AUC) + zβ
√
VA(AUC)
]2
(A−A0)2   
 where  VA(AUC)=n+VarA(AUC) .  
The pooled prevalence from three recent CoMiSS 
trials of children with a positive OFC, that is, confirmed 
CMPA was 83%.10 Entry criterion for these studies was 
a CoMiSS  >12. For the present study, patients will be 
recruited based on symptoms and the estimated prev-
alence of CMPA in the study population will there-
fore lower (estimated prevalence of challenge-proven 
CMPA 70%). Based on the above asymptotic sample size 
formula and prevalence estimate for CMPA, around 80 
subjects with a positive OFC and 35 subjects with a nega-
tive OFC will be required in the holdout set to test the 
above hypothesis regarding the AUC with 90% power 
and at 5% level of significance and 2.5% for one-sided 
testing. Thus, the overall sample size accommodating the 
training and holdout set splits is N=2×115=230. Assuming 
a 15–20% dropout rate, 300 subjects will need to be 
enrolled.
Interim analysis
An interim analysis will is planned after 146 subjects have 
completed their OFC. At this point, there will be data 
from 73 subjects in the training set and 73 subjects in the 
holdout set. The interim analysis will be carried out in 
an unblinded fashion by an independent statistical centre 
and the interim decision will be taken by an independent 
data monitoring committee (iDMC) in a closed session. 
The sponsor will remain blinded to the interim data and 
will only be informed about the iDMC decision resulting 
from the interim analysis.
Based on an interim analysis at, the following decisions 
may be made:
1. Stopping for futility if the AUC is less than the desired 
0.75 benchmark.
2. Stopping for efficacy if the AUC is greater than 0.9.
3. Continuing the trial, as planned, if the AUC at the 
interim is close to 0.9.
4. Increase the sample size by a required amount (see 
below) if the interim results are promising but ob-
served prevalence, actual AUC or dropout rate at the 
interim are slightly different than the corresponding 
assumed design values.
datasets to be analysed
The intent-to-treat (ITT) population is defined as all 
randomised subjects who have attempted the OFC. Effi-
cacy and safety analyses will be based on the ITT popula-
tion. The per-protocol (PP) population is defined as all 
subjects who complete the study with no major protocol 
violations. Subjects who ingest CMP during the elimina-
tion diet and those who require treatment with antibi-
otics, antipyretics or corticosteroids during the study will 
be removed from the PP population but will be included 
in the full-analysis population. Every attempt will be made 
to collect final study data from subjects who withdraw 
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before completing the study. No imputation for missing 
data is planned for this study.
EthICs And dIssEMInAtIon
A written informed consent form will be signed by a parent 
or legal guardian before the study enrolment. Any modi-
fications to the protocol, which may affect the conduct 
of the study, potential benefits to the patients or patient 
safety, including changes to the study design, will be 
reported to the ethics committee for all necessary amend-
ments. All study-related information will be stored securely 
in the study sites in locked cabinets, in an area with limited 
access (databases will be secured with a password-protected 
access system). The findings of this validation trial will be 
submitted to a peer-reviewed journal (paediatric, allergy, 
nutrition and/or gastroenterology). All Chinese investiga-
tors will be involved in the development of the final manu-
script. Abstracts will be submitted to relevant national and 
international conferences.
study sPonsorshIP And ovErsIght
 The Contract Research Organisation, George Clinical, 
Sydney, Australia will be overseeing the overall conduct 
of the study, including adverse event monitoring and 
data management. Adverse events will be reported in the 
patient file. They will be assessed and managed according 
to good clinical practice. Adverse events are part of 
the secondary outcomes and will be listed in the final 
study report. The independent statistical analysis will be 
performed by Cytel, Cambridge, Massachusetts, USA.
tIMElInEs
The study started recruitment in January 2017, and 
completion of data collection is anticipated by June 2018.
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